Pharmaceutical products are also known as drugs or medicines used for treating health issues and are invented for healthcare plans. Now with some top pharmaceutical or drug manufacturers that have proven to invent and promote better and efficient medical products and increased pharmaceutical sales with each passing year, there are some top effective products too. These products increase the sales of the pharmaceutical market and help improve the health system of Pakistan better too.
Some such products, that have proven to improve health conditions in the pharmaceutical market and have proven to be the top pharmaceutical products to increase the sales over time too, include;
- Humira(adalimumab)
- Eliquis(apixaban)
- Revlimid(lenalidomide)
- Keytruda( pembrolizumab)
- Enbrel( etanercept)
- Herceptin(trastuzumab)
- Avastin( bevacizumab)
- Eylea(aflibercept)
- Opdivo(nivolumab)
- Xarelto( rivaroxaban)
5 Top Selling Prescription Drugs:
- Humira:
This one’s Abbvie’s largest product that has achieved an increase in the net sale back in 2018, of about 7% worldwide, despite having bio-similar launched alongside in various places around the world. This drug is used to treat a number of autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ankylosing spondylitis, along with plaque psoriasis in various places of the world; namely US, Mexico, Europe, and Canada. This drug also achieved a total net revenue of 61% for this company back in 2018. - Eliquis:
This drug was initially launched in 2012 and is a factor Xa inhibitor anticoagulant which is approved to reduce the stroke risks and systemic embolism risk in the patients with its non-valvular atrial fibrillation. Eliquis is a firm and growing franchise of the BMS Company having a net sale growth of 32% in the year 2018. This drug was developed and commercialized by both BMS and Pfizer. As reported by Pfizer, the drug’s net sale growth increased by about 36% worldwide. - Revlimid:
Celgene’s Revlimid achieved an approximate year-by-year growth of 18% in the net sales during 2018, as a result of increased duration of treatments and market share. Since its initial approval in 2005, this drug works forth treating multiple diseases and conditions of myeloma, myelodysplastic syndromes, as well as the mantle cell lymphoma. The drug has shown successful results and improvements in treating various newly diagnosed multiple diseases that are likely mentioned. - Keytruda:
Merck’s keytruda is approved to treat almost 11 different types of cancers and has grown in net sales by almost 47% in the previous year. Its treatable cancers include; non-small cell lung cancer, head and neck squamous cell carcinoma, melanoma, and cervical cancer, in terms of monotherapy of such cancers along with other therapies. - Enbrel:
Enbrel which I manufactured by Amgen reported its net sale in the US and Canada of $5bn, where Pfizer reported its net sale of $2.1bn all around the world. This prescribed pharmaceutical product was launched in 998, mainly for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis. The net growth of this produced reduced by 8% in 2018 as compared to its net sale in 2017 due to the lower demand for the unit and its net selling price.
Although there are almost 10 worldwide top-selling pharmaceutical products/ prescribed drugs, we have shortly discussed the major top 5 selling pharmaceutical products that have made huge net sales in the pharma marketplace.
